Computational methods and tools to predict cytochrome P450 metabolism for drug discovery

In this review, we present important, recent developments in the computational prediction of cytochrome P450 (CYP) metabolism in the context of drug discovery. We discuss in silico models for the various aspects of CYP metabolism prediction, including CYP substrate and inhibitor predictors, site of metabolism predictors (i.e., metabolically labile sites within potential substrates) and metabolite structure predictors. We summarize the different approaches taken by these models, such as rule‐based methods, machine learning, data mining, quantum chemical methods, molecular interaction fields, and docking. We highlight the scope and limitations of each method and discuss future implications for the field of metabolism prediction in drug discovery.publishedVersio

AI in drug discovery and its clinical relevance

The COVID-19 pandemic has emphasized the need for novel drug discovery process. However, the journey from conceptualizing a drug to its eventual implementation in clinical settings is a long, complex, and expensive process, with many potential points of failure. Over the past decade, a vast growth in medical information has coincided with advances in computational hardware (cloud computing, GPUs, and TPUs) and the rise of deep learning. Medical data generated from large molecular screening profiles, personal health or pathology records, and public health organizations could benefit from analysis by Artificial Intelligence (AI) approaches to speed up and prevent failures in the drug discovery pipeline. We present applications of AI at various stages of drug discovery pipelines, including the inherently computational approaches of de novo design and prediction of a drug's likely properties. Open-source databases and AI-based software tools that facilitate drug design are discussed along with their associated problems of molecule representation, data collection, complexity, labeling, and disparities among labels. How contemporary AI methods, such as graph neural networks, reinforcement learning, and generated models, along with structure-based methods, (i.e., molecular dynamics simulations and molecular docking) can contribute to drug discovery applications and analysis of drug responses is also explored. Finally, recent developments and investments in AI-based start-up companies for biotechnology, drug design and their current progress, hopes and promotions are discussed in this article.  Other InformationPublished in:HeliyonLicense: https://creativecommons.org/licenses/by/4.0/See article on publisher's website: https://doi.org/10.1016/j.heliyon.2023.e17575 </p

Practically Useful: What the Rosetta Protein Modeling Suite Can Do for You

The objective of this review is to enable researchers to use the software package ROSETTA for biochemical and biomedicinal studies. We provide a brief review of the six most frequent research problems tackled with ROSETTA. For each of these six tasks, we provide a tutorial that illustrates a basic ROSETTA protocol. The ROSETTA method was originally developed for de novo protein structure prediction and is regularly one of the best performers in the community-wide biennial Critical Assessment of Structure Prediction. Predictions for protein domains with fewer than 125 amino acids regularly have a backbone root-mean-square deviation of better than 5.0 A ˚. More impressively, there are several cases in which ROSETTA has been used to predict structures with atomic level accuracy better than 2.5 A ˚. In addition to de novo structure prediction, ROSETTA also has methods for molecular docking, homology modeling, determining protein structures from sparse experimental NMR or EPR data, and protein design. ROSETTA has been used to accurately design a novel protein structure, predict the structure of protein-protein complexes, design altered specificity protein-protein and protein-DNA interactions, and stabilize proteins and protein complexes. Most recently, ROSETTA has been used to solve the X-ray crystallographic phase problem. ROSETTA is a unified software package for protein structure prediction and functional design. It has been used to predic

Machine Learning Small Molecule Properties in Drug Discovery

Machine learning (ML) is a promising approach for predicting small molecule properties in drug discovery. Here, we provide a comprehensive overview of various ML methods introduced for this purpose in recent years. We review a wide range of properties, including binding affinities, solubility, and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). We discuss existing popular datasets and molecular descriptors and embeddings, such as chemical fingerprints and graph-based neural networks. We highlight also challenges of predicting and optimizing multiple properties during hit-to-lead and lead optimization stages of drug discovery and explore briefly possible multi-objective optimization techniques that can be used to balance diverse properties while optimizing lead candidates. Finally, techniques to provide an understanding of model predictions, especially for critical decision-making in drug discovery are assessed. Overall, this review provides insights into the landscape of ML models for small molecule property predictions in drug discovery. So far, there are multiple diverse approaches, but their performances are often comparable. Neural networks, while more flexible, do not always outperform simpler models. This shows that the availability of high-quality training data remains crucial for training accurate models and there is a need for standardized benchmarks, additional performance metrics, and best practices to enable richer comparisons between the different techniques and models that can shed a better light on the differences between the many techniques.Comment: 46 pages, 1 figur

Development of Machine Learning Models for Generation and Activity Prediction of the Protein Tyrosine Kinase Inhibitors

The field of computational drug discovery and development continues to grow at a rapid pace, using generative machine learning approaches to present us with solutions to high dimensional and complex problems in drug discovery and design. In this work, we present a platform of Machine Learning based approaches for generation and scoring of novel kinase inhibitor molecules. We utilized a binary Random Forest classification model to develop a Machine Learning based scoring function to evaluate the generated molecules on Kinase Inhibition Likelihood. By training the model on several chemical features of each known kinase inhibitor, we were able to create a metric that captures the differences between a SRC Kinase Inhibitor and a non-SRC Kinase Inhibitor. We implemented the scoring function into a Biased and Unbiased Bayesian Optimization framework to generate molecules based on features of SRC Kinase Inhibitors. We then used similarity metrics such as Tanimoto Similarity to assess their closeness to that of known SRC Kinase Inhibitors. The molecules generated from this experiment demonstrated potential for belonging to the SRC Kinase Inhibitor family though chemical synthesis would be needed to confirm the results. The top molecules generated from the Unbiased and Biased Bayesian Optimization experiments were calculated to respectively have Tanimoto Similarity scores of 0.711 and 0.709 to known SRC Kinase Inhibitors. With calculated Kinase Inhibition Likelihood scores of 0.586 and 0.575, the top molecules generated from the Bayesian Optimization demonstrate a disconnect between the similarity scores to known SRC Kinase Inhibitors and the calculated Kinase Inhibition Likelihood score. It was found that implementing a bias into the Bayesian Optimization process had little effect on the quality of generated molecules. In addition, several molecules generated from the Bayesian Optimization process were sent to the School of Pharmacy for chemical synthesis which gives the experiment more concrete results. The results of this study demonstrated that generating molecules throughBayesian Optimization techniques could aid in the generation of molecules for a specific kinase family, but further expansions of the techniques would be needed for substantial results